Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype.

Hirt UA, Waizenegger IC, Schweifer N, Haslinger C, Gerlach D, Braunger J, Weyer-Czernilofsky U, Stadtmüller H, Sapountzis I, Bader G, Zoephel A, Bister B, Baum A, Quant J, Kraut N, Garin-Chesa P, Adolf GR.

Oncogenesis. 2018 Feb 23;7(2):21. doi: 10.1038/s41389-018-0032-z.

2.

The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy.

Sanderson MP, Hofmann MH, Garin-Chesa P, Schweifer N, Wernitznig A, Fischer S, Jeschko A, Meyer R, Moll J, Pecina T, Arnhof H, Weyer-Czernilofsky U, Zahn SK, Adolf GR, Kraut N.

Mol Cancer Ther. 2017 Oct;16(10):2223-2233. doi: 10.1158/1535-7163.MCT-17-0336. Epub 2017 Jul 20.

PMID:
28729397
3.

Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.

Sini P, Gürtler U, Zahn SK, Baumann C, Rudolph D, Baumgartinger R, Strauss E, Haslinger C, Tontsch-Grunt U, Waizenegger IC, Solca F, Bader G, Zoephel A, Treu M, Reiser U, Garin-Chesa P, Boehmelt G, Kraut N, Quant J, Adolf GR.

Mol Cancer Ther. 2016 Oct;15(10):2388-2398. Epub 2016 Aug 5.

4.

A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.

Waizenegger IC, Baum A, Steurer S, Stadtmüller H, Bader G, Schaaf O, Garin-Chesa P, Schlattl A, Schweifer N, Haslinger C, Colbatzky F, Mousa S, Kalkuhl A, Kraut N, Adolf GR.

Mol Cancer Ther. 2016 Mar;15(3):354-65. doi: 10.1158/1535-7163.MCT-15-0617. Epub 2016 Feb 25.

5.

BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis.

Sanderson MP, Apgar J, Garin-Chesa P, Hofmann MH, Kessler D, Quant J, Savchenko A, Schaaf O, Treu M, Tye H, Zahn SK, Zoephel A, Haaksma E, Adolf GR, Kraut N.

Mol Cancer Ther. 2015 Dec;14(12):2762-72. doi: 10.1158/1535-7163.MCT-15-0539. Epub 2015 Oct 5.

6.

Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.

Rudolph D, Impagnatiello MA, Blaukopf C, Sommer C, Gerlich DW, Roth M, Tontsch-Grunt U, Wernitznig A, Savarese F, Hofmann MH, Albrecht C, Geiselmann L, Reschke M, Garin-Chesa P, Zuber J, Moll J, Adolf GR, Kraut N.

J Pharmacol Exp Ther. 2015 Mar;352(3):579-89. doi: 10.1124/jpet.114.221150. Epub 2015 Jan 9.

7.

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.

Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR.

J Pharmacol Exp Ther. 2012 Nov;343(2):342-50. doi: 10.1124/jpet.112.197756. Epub 2012 Aug 10.

8.

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.

Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E, Baum A, Lamche H, Küpcü Z, Jacobi A, Müller S, Hirt U, Adolf GR, Borges E.

Blood. 2011 Oct 13;118(15):4159-68. doi: 10.1182/blood-2011-04-351932. Epub 2011 Jul 27.

9.

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.

Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, Adolf GR.

Clin Cancer Res. 2009 May 1;15(9):3094-102. doi: 10.1158/1078-0432.CCR-08-2445. Epub 2009 Apr 21.

10.

Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts.

Ostermann E, Garin-Chesa P, Heider KH, Kalat M, Lamche H, Puri C, Kerjaschki D, Rettig WJ, Adolf GR.

Clin Cancer Res. 2008 Jul 15;14(14):4584-92. doi: 10.1158/1078-0432.CCR-07-5211.

11.

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ.

Curr Biol. 2007 Feb 20;17(4):316-22. Epub 2007 Feb 8.

12.

Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts.

Verel I, Heider KH, Siegmund M, Ostermann E, Patzelt E, Sproll M, Snow GB, Adolf GR, van Dongen GA.

Int J Cancer. 2002 May 20;99(3):396-402.

13.

Identification and characterization of 9D7, a novel human protein overexpressed in renal cell carcinoma.

Klade CS, Dohnal A, Fürst W, Sommergruber W, Heider KH, Gharwan H, Ratschek M, Adolf GR.

Int J Cancer. 2002 Jan 10;97(2):217-24. Erratum in: Int J Cancer 2002 Apr 20;98(6):956.

14.

Identification of tumor antigens in renal cell carcinoma by serological proteome analysis.

Klade CS, Voss T, Krystek E, Ahorn H, Zatloukal K, Pummer K, Adolf GR.

Proteomics. 2001 Jul;1(7):890-8.

PMID:
11503213
15.

Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.

Stroomer JW, Roos JC, Sproll M, Quak JJ, Heider KH, Wilhelm BJ, Castelijns JA, Meyer R, Kwakkelstein MO, Snow GB, Adolf GR, van Dongen GA.

Clin Cancer Res. 2000 Aug;6(8):3046-55.

16.
17.
18.

Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas.

Heider KH, Sproll M, Susani S, Patzelt E, Beaumier P, Ostermann E, Ahorn H, Adolf GR.

Cancer Immunol Immunother. 1996 Dec;43(4):245-53.

PMID:
9003471
19.

Expression of CD44 isoforms in human skin cancer.

Simon JC, Heider KH, Dietrich A, Wuttig C, Schöpf E, Adolf GR, Ponta H, Herrlich P.

Eur J Cancer. 1996 Jul;32A(8):1394-400.

PMID:
8869105
20.

Expression of CD44 isoforms in human renal cell carcinomas.

Heider KH, Ratschek M, Zatloukal K, Adolf GR.

Virchows Arch. 1996 Jul;428(4-5):267-73.

PMID:
8764936
21.

Expression of CD44v6 in ulcerative colitis and Crohn's disease.

Reinisch W, Heider KH, Oberhuber G, Dejaco C, Adolf GR.

Lancet. 1996 Apr 13;347(9007):1049. No abstract available.

PMID:
8606594
22.

Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys.

Heider KH, Mulder JW, Ostermann E, Susani S, Patzelt E, Pals ST, Adolf GR.

Eur J Cancer. 1995 Dec;31A(13-14):2385-91.

PMID:
8652273
23.

Prognostic value of CD44 splice variant expression in ovarian cancer.

Uhl-Steidl M, Müller-Holzner E, Zeimet AG, Adolf GR, Daxenbichler G, Marth C, Dapunt O.

Oncology. 1995 Sep-Oct;52(5):400-6.

PMID:
7543667
24.

Human interferon omega--a review.

Adolf GR.

Mult Scler. 1995;1 Suppl 1:S44-7. Review.

PMID:
9345398
25.

Tumor necrosis factor (TNF)-dependent shedding of the p55 TNF receptor in a baboon model of bacteremia.

Redl H, Schlag G, Adolf GR, Natmessnig B, Davies J.

Infect Immun. 1995 Jan;63(1):297-300.

26.

Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis.

Mulder JW, Wielenga VJ, Polak MM, van den Berg FM, Adolf GR, Herrlich P, Pals ST, Offerhaus GJ.

Gut. 1995 Jan;36(1):76-80.

27.

Proteins induced by recombinant equine interferon-beta 1 within equine peripheral blood mononuclear cells and polymorphonuclear neutrophilic granulocytes.

Heinz H, Marquardt J, Schuberth HJ, Adolf GR, Leibold W.

Vet Immunol Immunopathol. 1994 Sep;42(3-4):221-35.

PMID:
7810057
29.

Regulation of the expression of annexin VIII in acute promyelocytic leukemia.

Sarkar A, Yang P, Fan YH, Mu ZM, Hauptmann R, Adolf GR, Stass SA, Chang KS.

Blood. 1994 Jul 1;84(1):279-86.

30.

Expression of CD44 splice variants during lymphocyte activation and tumor progression.

Griffioen AW, Horst E, Heider KH, Wielenga VJ, Adolf GR, Herrlich P, Pals ST.

Cell Adhes Commun. 1994 Jul;2(3):195-200.

PMID:
7530151
31.

Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression.

Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST.

Cancer Res. 1993 Oct 15;53(20):4754-6.

32.

CD44 splice variants: expression during lymphocyte activation and tumor progression.

Pals ST, Koopman G, Heider KH, Griffioen A, Adolf GR, Van den Berg F, Ponta H, Herrlich P, Horst E.

Behring Inst Mitt. 1993 Aug;(92):273-7. Review.

PMID:
7504454
33.

Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44.

Koopman G, Heider KH, Horst E, Adolf GR, van den Berg F, Ponta H, Herrlich P, Pals ST.

J Exp Med. 1993 Apr 1;177(4):897-904.

36.

Constitutive production of interferon-alpha 2 by a human B-lymphoblastoid cell line.

Adolf GR, Pieler C, Maurer-Fogy I.

J Interferon Res. 1992 Aug;12(4):275-80.

PMID:
1431307
37.

Monitoring of effects induced by recombinant equine interferon-beta 1 in whole blood and separated fractions of peripheral blood of horses.

Marquardt J, Heymer J, Heinz H, Deegen E, Adolf GR, Leibold W.

Zentralbl Veterinarmed B. 1992 Jul;39(5):327-36.

PMID:
1325723
38.
39.

A method for the assay of "difficult" interferons exemplified with recombinant equine interferon-beta 1.

Marquardt J, Heinz H, Heymer J, Deegen E, Adolf GR, Leibold W.

J Interferon Res. 1992 Apr;12(2):83-5.

PMID:
1315833
41.

Isolation and partial characterization of the human erythrocyte band 7 integral membrane protein.

Hiebl-Dirschmied CM, Adolf GR, Prohaska R.

Biochim Biophys Acta. 1991 Jun 18;1065(2):195-202.

PMID:
1711899
42.

Human interferon omega 1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein.

Adolf GR, Frühbeis B, Hauptmann R, Kalsner I, Maurer-Fogy I, Ostermann E, Patzelt E, Schwendenwein R, Sommergruber W, Zöphel A.

Biochim Biophys Acta. 1991 Jun 13;1089(2):167-74.

PMID:
1647209
43.

Natural human interferon-alpha 2 is O-glycosylated.

Adolf GR, Kalsner I, Ahorn H, Maurer-Fogy I, Cantell K.

Biochem J. 1991 Jun 1;276 ( Pt 2):511-8.

44.

Production of tumor necrosis factors alpha and beta by human mononuclear leukocytes stimulated with mitogens, bacteria, and malarial parasites.

Ferrante A, Staugas RE, Rowan-Kelly B, Bresatz S, Kumaratilake LM, Rzepczyk CM, Adolf GR.

Infect Immun. 1990 Dec;58(12):3996-4003.

45.

Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein.

Himmler A, Maurer-Fogy I, Krönke M, Scheurich P, Pfizenmaier K, Lantz M, Olsson I, Hauptmann R, Stratowa C, Adolf GR.

DNA Cell Biol. 1990 Dec;9(10):705-15.

PMID:
1702293
46.
47.

Highly sensitive enzyme immunoassay for human lymphotoxin (tumor necrosis factor beta) in serum.

Adolf GR, Lamche HR.

J Immunol Methods. 1990 Jul 3;130(2):177-85.

PMID:
2373867
48.

Purification and characterization of natural human interferon omega 1. Two alternative cleavage sites for the signal peptidase.

Adolf GR, Maurer-Fogy I, Kalsner I, Cantell K.

J Biol Chem. 1990 Jun 5;265(16):9290-5.

PMID:
1693148
49.

Recombinant equine interferon-beta 1: purification and preliminary characterization.

Adolf GR, Traxler E, Maurer-Fogy I.

J Interferon Res. 1990 Jun;10(3):255-67.

PMID:
2200832

Supplemental Content

Loading ...
Support Center